drugset / Trial / NCT03290079
Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
Phase 2
Completed
20 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to: * Assess overall radiographic response rate (ORR) * Assess progression-free survival (PFS) * Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
Timeline
- Start
- 2017-12-15
- Primary completion
- 2023-01-10
- Completion
- 2024-05-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | 20 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |